Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
6,174 | Dovepress* | 5,730+ | 1,175 | 6,905 | |
PubMed Central* | 444 | 238 | 682 | ||
Totals | 6,174 | 1,413 | 7,587 | ||
*Since 30 June 2016 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
3 | 0 | 0 | 0 | 1 | 2 |
View citations on PubMed and Google Scholar